Q-omics provides the consensus-scored KCTD15 profile across patient tissues and cancer cell-line models. KCTD15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCTD15 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, KCTD15 protein abundance shows 20,116 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where KCTD15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD15 survival associations across molecular data types. KCTD15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD15 RNA expression–survival associations across cancer types. High KCTD15 expression shows unfavorable associations in KIRP, ACC and BRCA, but favorable associations in UCS, LAML and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCTD15 RNA expression.
This table summarizes KCTD15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KCTD15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD15 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BRCA and LUSC. The HNSC box plot shows higher KCTD15 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with KCTD15 in patient tissues and cancer cell lines. In patient samples, KCTD15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
